慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是常见的慢性免疫介导的周围神经病。早期准确诊断对于及时治疗和预防不可逆的神经病变具有重要价值。为深入探讨CIDP诊疗现状和进展，共话解决之策，由北京整合医学学会主办的“神经免疫疾病学术交流会 ...

运动型CIDP：表现为相对对称的近端和远端无力，但在临床和电生理上感觉正常，与典型CIDP（感觉异常）和多灶性运动神经病（MMN，无力常为不对称且主要累及上肢）形成对比。如果临床上的运动型CIDP出现感觉神经传导异常，则诊断为运动为主型CIDP。运动型CIDP患者在使用皮质类固醇后可能会恶化。

Discovery of the antigenic targets associated with nerve-specific autoimmune diseases is a crucial step in understanding their pathogenesis The identification of highly disease-specific autoantibodies ...

Identification and correct diagnosis of the chronic acquired demyelinating polyneuropathies is important because they are immune-mediated and, therefore, amenable to treatment Early diagnosis and ...

As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

Chronic Inflammatory Demyelinating Polyneuropathy Companies such as Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies Inc., ...

日本大阪和马萨诸塞州坎布里奇--(BUSINESS WIRE)--(美国商业资讯)-- Takeda (TSE:4502/NYSE:TAK) 今天宣布，欧洲药品管理局(EMA)人用医药产品委员会(CHMP)建议批准HYQVIA ® [10%免疫球蛋白（人体）注射液结合重组人体透明质酸酶]用于慢性炎症性脱髓鞘性多神经病变(CIDP)患者 ...

日本大阪和马萨诸塞州剑桥--(BUSINESS WIRE)--(美国商业资讯)-- Takeda(TSE:4502/NYSE:TAK)今天公布了3期ADVANCE-CIDP 3临床试验的数据，这是 ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...